KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Xenon Pharmaceuticals (XENE) over the last 13 years, with Q3 2025 value amounting to $127.7 million.

  • Xenon Pharmaceuticals' Non-Current Assets fell 2755.16% to $127.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $642.3 million, marking a year-over-year decrease of 2564.05%. This contributed to the annual value of $162.9 million for FY2024, which is 4907.55% down from last year.
  • Per Xenon Pharmaceuticals' latest filing, its Non-Current Assets stood at $127.7 million for Q3 2025, which was down 2755.16% from $174.0 million recorded in Q2 2025.
  • Xenon Pharmaceuticals' Non-Current Assets' 5-year high stood at $319.8 million during Q4 2023, with a 5-year trough of $7.4 million in Q1 2021.
  • Moreover, its 5-year median value for Non-Current Assets was $140.3 million (2023), whereas its average is $121.8 million.
  • As far as peak fluctuations go, Xenon Pharmaceuticals' Non-Current Assets soared by 147528.3% in 2022, and later tumbled by 4907.55% in 2024.
  • Over the past 5 years, Xenon Pharmaceuticals' Non-Current Assets (Quarter) stood at $13.0 million in 2021, then soared by 1084.63% to $153.8 million in 2022, then soared by 107.89% to $319.8 million in 2023, then tumbled by 49.08% to $162.9 million in 2024, then fell by 21.6% to $127.7 million in 2025.
  • Its Non-Current Assets was $127.7 million in Q3 2025, compared to $174.0 million in Q2 2025 and $177.7 million in Q1 2025.